Inflammatory bowel disease: can omega-3 fatty acids really help?

Area of Science:

• Gastroenterology
• Immunology
• Nutritional Science

Background:

• Inflammatory bowel disease (IBD) management seeks adjunct therapies to improve treatment efficacy and patient quality of life.
• Omega-3 polyunsaturated fatty acids (ω3FA) are investigated for their potential anti-inflammatory properties in IBD.
• ω3FA may modulate inflammatory pathways by serving as precursors for anti-inflammatory mediators.

Purpose of the Study:

• To review the role of ω3FA as an adjuvant therapy in inflammatory bowel disease.
• To explore the mechanisms by which ω3FA may influence IBD pathogenesis and progression.
• To address controversies regarding ω3FA efficacy in IBD prevention and treatment.

Main Methods:

• Literature review of studies investigating ω3FA in the context of IBD.
• Analysis of proposed mechanisms of action for ω3FA, including eicosanoid and specialized pro-resolving mediator synthesis.
• Examination of effects on oxidative stress, cytokine production, and adhesion molecule expression.

Main Results:

• ω3FA are substrates for anti-inflammatory eicosanoids and specialized pro-resolving mediators (resolvins, maresins, protectins).
• Potential benefits include reduced oxidative stress, tumor necrosis factor-α, and proinflammatory cytokines.
• ω3FA may act as chemopreventive agents and decrease adhesion molecule expression in IBD.

Conclusions:

• The anti-inflammatory effects of ω3FA in IBD are considered incontestable, despite ongoing controversies regarding clinical outcomes.
• Further research is warranted to elucidate precise pathophysiological mechanisms.
• Establishing recommended daily intake for IBD prevention or remission induction requires additional investigation.